...
首页> 外文期刊>Journal of pharmacy practice >INR Management of an Antiphospholipid Syndrome Patient With Point-of-Care INR Testing
【24h】

INR Management of an Antiphospholipid Syndrome Patient With Point-of-Care INR Testing

机译:抗磷脂综合征患者用护理点测试的INR管理

获取原文
获取原文并翻译 | 示例

摘要

Management of patients with antiphospholipid syndrome on warfarin therapy can be challenging. The international normalized ratio (INR) of patients with antiphospholipid syndrome can be falsely elevated. This elevation is thought to be reflective of the reaction of the antiphospholipid antibody with the thromboplastin used to measure the protime. This false elevation can be seen in both venipuncture and point-of-care results. This discrepancy is usually more apparent in patients with whose INR is tested using point of care. As a result, there is a preference for venipuncture INR testing in most patients with antiphospholipid syndrome requiring warfarin therapy. In our case, we highlight one patient who we correlated her venipuncture INR with point-of-care INR as well as a chromogenic factor X level in order to manage her INR by point-of-care INR testing.
机译:抗磷脂综合征对华法林治疗综合征的患者可能具有挑战性。 抗磷脂综合征患者的国际规范化比率(INR)可以令人惊讶地升高。 认为该升高被认为是反射抗磷脂抗体与用于测量果实的血栓形成蛋白的反应。 在静脉穿刺和护理点结果中可以看到这种误升高。 在使用护理点测试其INR的患者中,这种差异通常更加明显。 结果,在大多数需要Warfarin治疗的抗磷脂综合征患者中静脉血inr检测偏好。 在我们的情况下,我们突出了一名患者,我们将她的静脉穿刺INR与护理点INR相关,以及发色因子X水平,以便通过护理点INR测试来管理她的INR。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号